Fluocinolone acetonide 0.01% in peanut oil: Therapy for childhood atopic dermatitis, even in patients who are peanut sensitive

Amy S. Paller, Sai Nimmagadda, Lawrence A Schachner, Susan B. Mallory, Teri Kahn, Isaac Willis, Lawrence F. Eichenfield

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Fluocinolone acetonide 0.01% in a blend of refined peanut and mineral oils has been used as treatment for scalp psoriasis for several years, but only more recently for atopic dermatitis. Objective: We sought to study the effectiveness for atopic dermatitis, potential for adrenal axis suppression, and safety of the fluocinolone acetonide 0.01% in oil in children with atopic dermatitis, including children with atopic dermatitis and peanut allergic sensitivity. Methods: Three separate studies were performed in children aged 2 to 12 years with atopic dermatitis: multicenter double-blind, randomized, and vehicle-controlled trial; cortisol stimulation testing; and prick testing, patch testing, and monitored medication use in children with peanut allergic sensitivity. Results: Improvement of ≥50% was demonstrated within 2 weeks in 81% to 87% of 81 patients treated with active medication versus 39% of 45 children treated with vehicle oil alone. No adrenal suppression occurred after 4 weeks of therapy in 32 patients. None of 9 patients who were peanut sensitive reacted to either the full formulation or vehicle in prick or patch testing; 20 children who were peanut sensitive showed no allergic reactions after application of the medication. Conclusion: Fluocinolone 0.01% in peanut oil is an effective alternative to the use of topical corticosteroid agents in ointment, cream, and lotion forms in children. No evidence of adrenal suppression or adverse local effects were demonstrated in these studies. The medication was well tolerated in patients with peanut allergic sensitivity.

Original languageEnglish
Pages (from-to)569-577
Number of pages9
JournalJournal of the American Academy of Dermatology
Volume48
Issue number4
DOIs
StatePublished - Apr 1 2003
Externally publishedYes

Fingerprint

Fluocinolone Acetonide
Atopic Dermatitis
Therapeutics
Oils
Mineral Oil
Ointments
arachis oil
Arachis
Scalp
Psoriasis
Hydrocortisone
Adrenal Cortex Hormones
Hypersensitivity
Randomized Controlled Trials
Safety

ASJC Scopus subject areas

  • Dermatology

Cite this

Fluocinolone acetonide 0.01% in peanut oil : Therapy for childhood atopic dermatitis, even in patients who are peanut sensitive. / Paller, Amy S.; Nimmagadda, Sai; Schachner, Lawrence A; Mallory, Susan B.; Kahn, Teri; Willis, Isaac; Eichenfield, Lawrence F.

In: Journal of the American Academy of Dermatology, Vol. 48, No. 4, 01.04.2003, p. 569-577.

Research output: Contribution to journalArticle

Paller, Amy S. ; Nimmagadda, Sai ; Schachner, Lawrence A ; Mallory, Susan B. ; Kahn, Teri ; Willis, Isaac ; Eichenfield, Lawrence F. / Fluocinolone acetonide 0.01% in peanut oil : Therapy for childhood atopic dermatitis, even in patients who are peanut sensitive. In: Journal of the American Academy of Dermatology. 2003 ; Vol. 48, No. 4. pp. 569-577.
@article{effc328ca6104eb1bb2500c53abf9e69,
title = "Fluocinolone acetonide 0.01{\%} in peanut oil: Therapy for childhood atopic dermatitis, even in patients who are peanut sensitive",
abstract = "Background: Fluocinolone acetonide 0.01{\%} in a blend of refined peanut and mineral oils has been used as treatment for scalp psoriasis for several years, but only more recently for atopic dermatitis. Objective: We sought to study the effectiveness for atopic dermatitis, potential for adrenal axis suppression, and safety of the fluocinolone acetonide 0.01{\%} in oil in children with atopic dermatitis, including children with atopic dermatitis and peanut allergic sensitivity. Methods: Three separate studies were performed in children aged 2 to 12 years with atopic dermatitis: multicenter double-blind, randomized, and vehicle-controlled trial; cortisol stimulation testing; and prick testing, patch testing, and monitored medication use in children with peanut allergic sensitivity. Results: Improvement of ≥50{\%} was demonstrated within 2 weeks in 81{\%} to 87{\%} of 81 patients treated with active medication versus 39{\%} of 45 children treated with vehicle oil alone. No adrenal suppression occurred after 4 weeks of therapy in 32 patients. None of 9 patients who were peanut sensitive reacted to either the full formulation or vehicle in prick or patch testing; 20 children who were peanut sensitive showed no allergic reactions after application of the medication. Conclusion: Fluocinolone 0.01{\%} in peanut oil is an effective alternative to the use of topical corticosteroid agents in ointment, cream, and lotion forms in children. No evidence of adrenal suppression or adverse local effects were demonstrated in these studies. The medication was well tolerated in patients with peanut allergic sensitivity.",
author = "Paller, {Amy S.} and Sai Nimmagadda and Schachner, {Lawrence A} and Mallory, {Susan B.} and Teri Kahn and Isaac Willis and Eichenfield, {Lawrence F.}",
year = "2003",
month = "4",
day = "1",
doi = "10.1067/mjd.2003.174",
language = "English",
volume = "48",
pages = "569--577",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Fluocinolone acetonide 0.01% in peanut oil

T2 - Therapy for childhood atopic dermatitis, even in patients who are peanut sensitive

AU - Paller, Amy S.

AU - Nimmagadda, Sai

AU - Schachner, Lawrence A

AU - Mallory, Susan B.

AU - Kahn, Teri

AU - Willis, Isaac

AU - Eichenfield, Lawrence F.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Background: Fluocinolone acetonide 0.01% in a blend of refined peanut and mineral oils has been used as treatment for scalp psoriasis for several years, but only more recently for atopic dermatitis. Objective: We sought to study the effectiveness for atopic dermatitis, potential for adrenal axis suppression, and safety of the fluocinolone acetonide 0.01% in oil in children with atopic dermatitis, including children with atopic dermatitis and peanut allergic sensitivity. Methods: Three separate studies were performed in children aged 2 to 12 years with atopic dermatitis: multicenter double-blind, randomized, and vehicle-controlled trial; cortisol stimulation testing; and prick testing, patch testing, and monitored medication use in children with peanut allergic sensitivity. Results: Improvement of ≥50% was demonstrated within 2 weeks in 81% to 87% of 81 patients treated with active medication versus 39% of 45 children treated with vehicle oil alone. No adrenal suppression occurred after 4 weeks of therapy in 32 patients. None of 9 patients who were peanut sensitive reacted to either the full formulation or vehicle in prick or patch testing; 20 children who were peanut sensitive showed no allergic reactions after application of the medication. Conclusion: Fluocinolone 0.01% in peanut oil is an effective alternative to the use of topical corticosteroid agents in ointment, cream, and lotion forms in children. No evidence of adrenal suppression or adverse local effects were demonstrated in these studies. The medication was well tolerated in patients with peanut allergic sensitivity.

AB - Background: Fluocinolone acetonide 0.01% in a blend of refined peanut and mineral oils has been used as treatment for scalp psoriasis for several years, but only more recently for atopic dermatitis. Objective: We sought to study the effectiveness for atopic dermatitis, potential for adrenal axis suppression, and safety of the fluocinolone acetonide 0.01% in oil in children with atopic dermatitis, including children with atopic dermatitis and peanut allergic sensitivity. Methods: Three separate studies were performed in children aged 2 to 12 years with atopic dermatitis: multicenter double-blind, randomized, and vehicle-controlled trial; cortisol stimulation testing; and prick testing, patch testing, and monitored medication use in children with peanut allergic sensitivity. Results: Improvement of ≥50% was demonstrated within 2 weeks in 81% to 87% of 81 patients treated with active medication versus 39% of 45 children treated with vehicle oil alone. No adrenal suppression occurred after 4 weeks of therapy in 32 patients. None of 9 patients who were peanut sensitive reacted to either the full formulation or vehicle in prick or patch testing; 20 children who were peanut sensitive showed no allergic reactions after application of the medication. Conclusion: Fluocinolone 0.01% in peanut oil is an effective alternative to the use of topical corticosteroid agents in ointment, cream, and lotion forms in children. No evidence of adrenal suppression or adverse local effects were demonstrated in these studies. The medication was well tolerated in patients with peanut allergic sensitivity.

UR - http://www.scopus.com/inward/record.url?scp=0037381528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037381528&partnerID=8YFLogxK

U2 - 10.1067/mjd.2003.174

DO - 10.1067/mjd.2003.174

M3 - Article

C2 - 12664021

AN - SCOPUS:0037381528

VL - 48

SP - 569

EP - 577

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 4

ER -